Application Notes

Cellastim S – Reconstitution Application Note

rHSA Reconstitution Video Protocol

Expansion of Adherent HEK293T Cells in Flasks in Chemically Defined Cell Culture Media

Lentivirus Production Protocol in Serum-Free Conditions – How To Improve Transfection Efficiency and Titer Yield

Transient Transfection Protocol – Enhancement of Transfection Efficiency Using Recombinant Transferrin with Serum-Free HEK293 Media

Blog

Controlling Impurities in Cell Culture Media

Evolving Challenges in Closed-System Biomanufacturing

High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media

How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development

Innovative Solutions in Closed-System Biomanufacturing: Exploring the Tools and Technologies Driving Sterility and Efficiency

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

Posters

Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times

Exbumin®, an EMA and FDA Approved Excipient, Provides Improved Performance and Stability in Vaccine Development and Final Formulations

Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin

Product Brochures

ITSE AF – Brochure

Optiferrin – Product Brochure

Product Specifications

ITS – Specifications

SDS

ITSE AF – Safety Data Sheet

Use Guidelines

Cellastim S – Guidelines for Use

ITS – Guidelines for Use

ITSE AF – Guidelines for Use

ITSE+A – Guidelines for Use

Optiferrin – Guidelines for Use

OptiVERO – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

White Papers

Emergence of Blood-Free Recombinant Human Albumin

Process Optimization for Lentivirus Production in the iCELLis® Nano Using a Chemically Defined, Animal Component Free HEK293 Media